Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fabry Disease

Conditions

Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)

Trial Timeline

Dec 1, 2002 → Aug 1, 2003

NCT ID

NCT00837824

About Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)

Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00837824. Target conditions include Fabry Disease, Chronic Kidney Disease, Stage IV (Severe).

What happened to similar drugs?

9 of 20 similar drugs in Fabry Disease were approved

Approved (9) Terminated (4) Active (10)

✅agalsidase betaSanofiApproved

✅Fabrazyme (agalsidase beta)SanofiApproved

✅agalsidase betaSanofiApproved

✅AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved

✅Agalsidase betaSanofiApproved

✅agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved

✅Agalsidase betaSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00837824	Phase 2	Terminated	Dec 1, 2002	Aug 1, 2003	Fabry Disease

Competing Products

20 competing products in Fabry Disease

See all competitors

Product	Company	Stage	Hype Score
Lucerastat	Idorsia	Phase 3	38
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Venglustat (GZ402671) + Placebo	Sanofi	Phase 3	44
agalsidase beta	Sanofi	Approved	35
Tropicamide	Sanofi	Pre-clinical	26
Fabrazyme (agalsidase beta)	Sanofi	Approved	35
agalsidase beta	Sanofi	Approved	43
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine	Sanofi	Approved	43
Gabapentin + placebo	Sanofi	Phase 2	27
Agalsidase beta	Sanofi	Approved	43
GZ/SAR402671	Sanofi	Phase 2	35
agalsidase beta (GZ419828) + agalsidase alfa	Sanofi	Approved	35
Fabrazyme (agalsidase beta)	Sanofi	Phase 3	40
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat	Sanofi	Phase 3	44
Iohexol	Sanofi	Phase 1	21
GZ/SAR402671	Sanofi	Phase 2	35
Fabrazyme (agalsidase beta)	Sanofi	Phase 2	35
Agalsidase beta	Sanofi	Approved	43
Fabrazyme (agalsidase beta) + Placebo	Sanofi	Approved	43
Agalsidase beta + Agalsidase beta	Sanofi	Phase 3	40